{"id":"calcipotriene-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation"},{"rate":null,"effect":"Burning sensation"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Hypercalcemia (with excessive use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcipotriene acts as a selective vitamin D receptor agonist, promoting normal differentiation and maturation of keratinocytes while inhibiting their proliferation. This mechanism helps normalize the abnormal skin cell turnover seen in psoriatic plaques. The foam formulation enhances penetration and patient compliance compared to traditional topical formulations.","oneSentence":"Calcipotriene is a vitamin D3 analog that binds to vitamin D receptors on skin cells to regulate cell proliferation and differentiation, reducing excessive skin cell growth characteristic of psoriasis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:42.060Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriasis vulgaris"}]},"trialDetails":[{"nctId":"NCT05185258","phase":"PHASE4","title":"Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-02-16","conditions":"Psoriasis Vulgaris, Psoriasis, Skin Diseases","enrollment":12},{"nctId":"NCT03806790","phase":"PHASE3","title":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-01-24","conditions":"Psoriasis Vulgaris","enrollment":182},{"nctId":"NCT01866163","phase":"PHASE3","title":"LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-06","conditions":"Psoriasis Vulgaris","enrollment":426},{"nctId":"NCT02132936","phase":"PHASE3","title":"LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-06","conditions":"Psoriasis Vulgaris","enrollment":504},{"nctId":"NCT02310646","phase":"PHASE3","title":"Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01","conditions":"Psoriasis Vulgaris","enrollment":219},{"nctId":"NCT02518048","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-08","conditions":"Skin and Connective Tissue Diseases","enrollment":35},{"nctId":"NCT01536886","phase":"PHASE2","title":"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":376},{"nctId":"NCT01536938","phase":"PHASE2","title":"LEO 90100 in the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":303},{"nctId":"NCT02416258","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Skin and Connective Tissue Diseases","enrollment":50},{"nctId":"NCT03442244","phase":"PHASE1","title":"Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-01-30","conditions":"Psoriasis Vulgaris","enrollment":20},{"nctId":"NCT03476746","phase":"PHASE1","title":"Dermatopharmacokinetic Trial of LEO 90100 Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-03-20","conditions":"Healthy","enrollment":58},{"nctId":"NCT04227288","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-01","conditions":"Nail Psoriasis","enrollment":6},{"nctId":"NCT05249972","phase":"PHASE3","title":"A Phase III Study in Subjects With Mild to Moderate Psoriasis.","status":"UNKNOWN","sponsor":"Lipidor AB","startDate":"2022-01-24","conditions":"Mild to Moderate Psoriasis","enrollment":294},{"nctId":"NCT04580537","phase":"PHASE2","title":"Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2020-10-02","conditions":"Nail Psoriasis","enrollment":11},{"nctId":"NCT04380597","phase":"","title":"Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life","status":"COMPLETED","sponsor":"Angeles Florez","startDate":"2019-03-26","conditions":"Nail Psoriasis","enrollment":10},{"nctId":"NCT02935582","phase":"","title":"PSOREAL - Managing PSOriasis in the REAL World","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-01","conditions":"Psoriasis Vulgaris","enrollment":1214},{"nctId":"NCT03506477","phase":"PHASE4","title":"Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":"Plaque Psoriasis, Psoriasis","enrollment":25},{"nctId":"NCT03996252","phase":"EARLY_PHASE1","title":"Combination Topical Therapy for Treatment of Scalp Actinic Keratoses","status":"TERMINATED","sponsor":"Tulane University","startDate":"2019-07-01","conditions":"Actinic Keratoses","enrollment":15},{"nctId":"NCT04571151","phase":"PHASE4","title":"Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis","status":"UNKNOWN","sponsor":"Skin Sciences, PLLC","startDate":"2021-01","conditions":"Plaque Psoriasis","enrollment":30},{"nctId":"NCT04555707","phase":"PHASE4","title":"The Maintenance Effect of Enstilar Foam in Combination With Otezla","status":"UNKNOWN","sponsor":"Derm Research, PLLC","startDate":"2020-06-24","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT03848871","phase":"PHASE4","title":"The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2017-12-12","conditions":"Plaque Psoriasis","enrollment":20},{"nctId":"NCT03731091","phase":"PHASE3","title":"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2018-10-31","conditions":"Psoriasis Vulgaris","enrollment":494},{"nctId":"NCT04372277","phase":"PHASE4","title":"Taltz in Combination With Enstilar for Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-28","conditions":"Psoriasis","enrollment":25},{"nctId":"NCT02881346","phase":"","title":"Efficacy and Tolerability of Enstilar® in Daily Practice","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-09","conditions":"Plaque Psoriasis","enrollment":410},{"nctId":"NCT02858713","phase":"PHASE4","title":"Adherence in Topical Treatment of Psoriasis","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2017-01-09","conditions":"Adherence","enrollment":134},{"nctId":"NCT03584360","phase":"PHASE2","title":"Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-09-24","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT03441789","phase":"PHASE4","title":"Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"L.H. Kircik, M.D.","startDate":"2017-09-18","conditions":"Plaque Psoriasis","enrollment":28},{"nctId":"NCT03827876","phase":"PHASE4","title":"Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2019-01-16","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT01582932","phase":"PHASE1","title":"Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Mayne Pharma International Pty Ltd","startDate":"2013-04","conditions":"Psoriasis","enrollment":36},{"nctId":"NCT01563068","phase":"PHASE1","title":"Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis","status":"COMPLETED","sponsor":"Mayne Pharma International Pty Ltd","startDate":"2012-04","conditions":"Psoriasis","enrollment":18},{"nctId":"NCT03080545","phase":"PHASE4","title":"Enstilar in Combination With Biologic Agents","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2017-05-01","conditions":"Psoriasis","enrollment":25},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT01139580","phase":"PHASE3","title":"The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-05","conditions":"Psoriasis","enrollment":363},{"nctId":"NCT00688519","phase":"PHASE3","title":"Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-03","conditions":"Psoriasis","enrollment":336},{"nctId":"NCT01745133","phase":"PHASE4","title":"Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Leon Kircik, M.D.","startDate":"2013-01","conditions":"Psoriasis","enrollment":63},{"nctId":"NCT00689481","phase":"PHASE3","title":"Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-03","conditions":"Psoriasis","enrollment":323}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Calcipotriene Foam","genericName":"Calcipotriene Foam","companyName":"Stiefel, a GSK Company","companyId":"stiefel-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcipotriene is a vitamin D3 analog that binds to vitamin D receptors on skin cells to regulate cell proliferation and differentiation, reducing excessive skin cell growth characteristic of psoriasis. Used for Plaque psoriasis, Psoriasis vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}